FDA Generic Drugs Division probe
Executive Summary
In its account July 11 of Rep. Dingell's probe of possible improprieties in the Generic Drug Division's ANDA approval procedures, "The Pink Sheet" identified five staffers who had been the subject of a previous investigation in 1980. Two of those involved in the 1980 probe -- reviewers Mary Jarski and Geraldine Millar -- have since departed from the Generic Drugs Division and have no connection to the current Dingell review.
You may also be interested in...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: